Marian Glynn, PhD, DABT, is the founder and principal consultant of Tox Clarity. She possesses niche expertise in topical drug product development and has advanced therapies for a range of indications in the fields of dermatology and ophthalmology including wound healing, lice infestation, psoriasis, atopic dermatitis, scleroderma, pruritus, scarring, warts, acne vulgaris, onychomycosis, basal cell carcinoma, actinic keratosis, and rosacea, as well as blepharitis, cataracts, and macular degeneration. Her experience also is deep in the field of hemophilia.
Prior to establishing her independent consultancy, Marian provided nonclinical regulatory strategy and toxicology operations services through Dow Pharmaceutical Sciences, Inc, a then industry leader in topical drug development. Additionally, she supported the Research and Development division of Valeant Pharmaceuticals North America (VPNA) from their acquisition of DPSI through their growth to the largest dermatology company in the United States. There, she trained under the astute guidance of Dr. Linda Mutter, PhD, DABT.